Teijin Limited announced the immediate availability of Revcovi 2.4 mg for intramuscular injection [Elapegademase (Genetic Recombination)]. With Revcovi 2.4 mg, Japan's first medication for Adenosine Deaminase (ADA) Deficiency, individuals with ADA Deficiency are expected to have improved ADA activity and immune system.
Clinigen Limited, a global pharmaceutical Products, and Services company, announced that Clinigen K.K., a fully owned subsidiary of Clinigen located in Tokyo, has gained manufacturing and marketing authorization for Hunterase (Idursulfase-beta) ICV 15mg as part of its strategic relationship with GC Pharma. The clearance of Hunterase ICV in Japan marks its first appearance in any nation globally.
Author Credits: Radhika Gupta, Shivam Bhutani